Drug Profile
Research programme: phosphatidylinositol 3 kinase alpha inhibitors - Intellikine/Numerate
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Intellikine; Numerate
- Developer Numerate; Takeda America Holdings
- Class Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 01 Jan 2012 Intellikine has been acquired and merged into Takeda America Holdings
- 12 Aug 2010 Early research in Cancer in USA (unspecified route)